Go Pro
NASDAQ:AIFC

ALT5 Sigma Q4 2025 Earnings Report

ALT5 Sigma logo
$0.60 0.00 (0.00%)
As of 07/2/2026 04:00 PM Eastern

ALT5 Sigma EPS Results

Actual EPS
-$6.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ALT5 Sigma Revenue Results

Actual Revenue
$5.37 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ALT5 Sigma Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Monday, April 13, 2026
Conference Call Time
8:00AM ET

ALT5 Sigma Earnings Headlines

SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.tc pixel
See More ALT5 Sigma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ALT5 Sigma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALT5 Sigma and other key companies, straight to your email.

About ALT5 Sigma

ALT5 Sigma (NASDAQ:AIFC) Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

View ALT5 Sigma Profile